Xilio Therapeutics, Inc. (XLO)
9.00
+0.09
(+1.01%)
USD |
NASDAQ |
Sep 09, 14:01
Xilio Therapeutics Gross Profit Margin (Quarterly) : 98.23% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 98.23% |
| March 31, 2026 | 97.28% |
| December 31, 2025 | 97.64% |
| September 30, 2025 | 98.22% |
| June 30, 2025 | 95.29% |
| Date | Value |
|---|---|
| March 31, 2025 | 83.04% |
| December 31, 2024 | 74.25% |
| September 30, 2024 | 82.32% |
| June 30, 2024 | 81.12% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Cue Biopharma, Inc. | 99.54% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -60.96% |
| Return on Assets | -14.71% |
| Return on Invested Capital | -51.05% |
| Profit Margin (Quarterly) | -34.09% |
| Operating Margin (Quarterly) | -18.68% |
| Return on Net Operating Assets | -163.2% |